Rejection of metastatic 4T1 breast cancer by attenuation of treg cells in combination with immune stimulation

Molecular Therapy

Volumn 15, Issue 12, 2007, Pages 2194-2202

  Chen, Li ^a   Huang, Tian Gui ^a   Meseck, Marcia ^a   Mandeli, John ^a   Fallon, John ^a   Woo, Savio L C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HOMODIMER; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; INTERLEUKIN 12; LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GENE ACTIVATION; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOSTIMULATION; LYMPHOCYTE FUNCTION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; OPTIMAL DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALIA; MURINAE; MUS;

EID: 36349037090     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300310     Document Type: Article

References (42)

1. Divino, CM, Chen, SH, Yang, W, Thung, S, Brower, ST and Woo, SL (2000). Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells. Breast Cancer Res Treat 60: 129-134.
2. Martinet O, Divino, CM, Zang, Y, Gan, Y, Mandeli, J, Thung, S et al (2000). T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther 9: 786-792.
3. + cells in the development of antitumor immunity. Cancer Res 64: 1130-1139.
4. Pulaski, BA, Terman, DS, Khan, S, Muller, E and Ostrand-Rosenberg, S (2000). Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CDBO for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 60 2710-2715.
5. Lohr, F, Hu, K, Haroon, Z, Samulski, TV, Huang, Q, Beaty, J et al. (2000). Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther 2: 195-203.
6. Rosenberg, SA, Yang, JC, Schwartzentruber, DJ, Hwu, P, Marincola, FM, Topalian, SL et al. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327.
7. Sarma, S, Guo, Y, Guilloux, Y, Lee, C, Bai, XF and Liu, Y (1999). Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A., normal development but restrained effector function in vivo. J Exp Med 189: 811-820.
8. Lee, KH, Wang, E, Nielsen, MB, Wunderlich, J, Migueles, S, Connors, M et al. (1999). Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163: 6292-6300.
9. + regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182: 18-32.
10. Zou, W (2006). Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307.
11. Knutson, KL (2006). Strong-arming immune regulation: Suppressing regulatory T-cell function to treat cancers. Future Oncol 2: 379-389.
12. Liyanage, UK, Moore, TT, loo, HG, Tanaka, Y, Herrmann, V, Doherty, G et al. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761.
13. + T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine (bigstar). Breast Cancer Res Treat 98: 17-29.
14. Klein, L, Khazaie, K and von Boehmer, H (2003). In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci USA 100: 8886-8891.
15. Zippelius, A, Batard, P, Rubio-Godoy, V, Bioley, G, Lienard, D, Lejeune, F et al. (2004). Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance. Cancer Res 64: 2865-2873.
16. + T cells. J Leukoc Bio 75: 785-791.
17. + regulatory T cells. J Immunol 173: 2428-2434.
18. + T cells and suppresses experimental autoimmune thyroiditis. J Immunol 170: 5511-5522.
19. + regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J Immunol 174: 7006-7013.
20. Tone, M, Tone, Y, Adams, E, Yates, SF, Frewin, MR, Cobbold, SP et al. (2003). Mouse glucocorticoid-incluced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci USA 100 15059-15064.
21. + regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3: 135-142.
22. Kim, JD, Choi, BK, Bae, JS, Lee, UH, Han, IS, Lee, HW et al. (2003). Cloning and characterization of GITR ligand. Genes Immun 4: 564-569.
23. Pulaski, B and Ostrand-Rosenberg, S. (2000). Mouse 4T1 breast tumor model. In: Coligan, JE, Bierer, B, Margulies, DH, Shevach, EM, Strober, W and Coico, R (eds). Current Protocols in Immunology, Vol. 4,. John Wiley: New York. pp. 20.2.1-20.2.16.
24. + regulatory T cells. J Exp Med 202: 885-891.
25. Calmels, B, Paul, S, Futin, N, Ledoux, C, Stoeckel, F and Acres, B (2005).Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. Cancer Gene Ther 12: 198-205.
26. + T cells. Trends Immunol 23: 378-380.
27. Zhou, G, Drake, CG and Levitsky, HI (2006). Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107: 628-636.
28. + T cells: A common basis between tumor immunity and autoimmunity. J Immunol 163:5211-5218.
29. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201 779-791.
30. + T cells blocks their inhibitory activity, a novel regulatory role for OX40 and its comparison with GITR. Blood 105: 2845-2851.
31. + T cells. J Immunol 173 5008-5020.
32. + regulatory T-cell activity: implications for neurodegeneration. J Neuroscience 24: 6133-6143.
33. + T-cell responses and tumor immunity. Cancer Res 66: 4904-4912.
34. Chen, ML, Pittet, MJ, Gorelik, L, Flavell, RA, Weissleder, R, von Boehmer, H et al. (2005). Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sd USA 102: 419-424.
35. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174 2591-2601.
36. Xu, DP, Sauter, BV, Huang, TG, Meseck, M, Woo, SL and Chen, SH (2005). The systemic administration of Ig-4 BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther 12 1526-1533.
37. Anderson, R, Macdonald, I, Corbett, T, Hacking, G, Lowdell, MW and Prentice, HG (1997). Construction and biologicall characterization of an interleukin-12 fusion protein (Flexi-12): Delivery to acute myeloid leukemic blasts using adeno-associated virus. Hum Gene Ther 8 1125-1135.
38. Aslakson, CJ and Miller, FR 992). Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405.
39. Corbett, TH, Griswold, DP Jr., Roberts, BJ, Peckham, JC and Schabel, FM Jr. (1975). Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434-2439.
40. Chen, L, Cohen, AC and Lewis, DB (2006). Impaired allogeneic activation and T-helper 1 differentiation of human cord blood naive CD4 T cells. Biol Blood Marrow Transplant 12: 160-171.
41. +FoxP3 regulatory T cells cultures with rapamycin. J Immunol 178: 320-329.
42. Lecoeur, H, Fevrier, M, Garcia, S, Riviere, Y and Gougeon, ML (2001). A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 253: 177-187.